Patient Access to Non-Approved Drugs
The new administration has expressed support for permitting patients to access non-approved drugs when they have a terminal diagnosis. Vice President Pence met with advocates of “Right to Try” legislation this week. The group advocates legislation in support of letting terminally ill patients to try drugs that have reached the third FDA approval phase.
The Vice President expressed the administrations support for the Right to Try law, which designed to give terminally ill patients hope by giving them access to experimental drugs that have already met FDA safety standards. President Trump has expressed his support for this opportunity stating “too many FDA rules generally pose unnecessary hurdles to drug approval”. This is completely consistent in his desire to streamline government regulations.
The FDA already has it own “compassionate use” program in place, while nearly half of the states have passed laws providing access to experimental drugs for the terminally ill.
It seems that this legislation could gain support from both sides of the isle as it poses no political issue that would make it a contentious fight. Moving experimental drugs to the terminally ill will not only provide them with hope, but it will also demonstrate the efficacy of the drug. This relaxing of regulations is something that the legislature, patients, providers and pharmaceutical companies can support.